monarchE
2020
Adjuvant Abemaciclib in High-Risk HR+/HER2– Early Breast Cancer
In 5,637 patients with HR+/HER2– node-positive high-risk early breast cancer, two years of abemaciclib added to endocrine therapy reduced invasive disease-free survival events compared with endocrine therapy alone.
Result
Efficacy: Invasive disease-free survivalHR 0.68
Below 1 favours two years of abemaciclib added to endocrine therapy, above 1 favours endocrine therapy alone.
- Absolute difference
- 7.6 points
The absolute difference is derived from the event rates.
Also reported: Distant relapse-free survival HR 0.675.
- Subtopic
- HR+/HER2– adjuvant
- Design
- Open-label RCT
- Relevance
- Important: one of several pillars.
- Source
- Johnston SRD, et al. J Clin Oncol. 2020;38(34):3987-3998; Rastogi P, et al. J Clin Oncol. 2024;42(9):987-993.doi 10.1200/JCO.20.02514
Discussion & critique
First CDK4/6 inhibitor with adjuvant benefit. OS data still maturing; benefit absolute but small in lower-risk subsets.